The completion of a successful phase I clinical study in SLE patients and phase II in Sjogren's syndrome patients (both conducted by Amgen Inc.)demonstrated efficacy of the human anti-ICOSL mAb, prezalumab [40, 41]. This evidence concerns the gene ICOSLG and systemic lupus erythematosus.